Morgan Stanley upgrades Doximity amid market confidence
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 13 Jan 26
Source: Benzinga
Doximity Inc. shares fell 4.24% and hit a 52-week low during regular trading.
Despite a 16% decline in the past year, Morgan Stanley upgraded Doximity to overweight, projecting its price to rise from $62 to $65, indicating market confidence in its future growth potential. This upgrade comes amid a broader market decline, with the Nasdaq-100 down 0.44% and the S&P 500 down 0.39%.
The upgrade suggests that investors may see Doximity as undervalued, and the anticipated price increase reflects optimism about its performance in the technology sector, which is expected to drive earnings growth in the coming quarters.
Analyst Views on DOCS
Wall Street analysts forecast DOCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOCS is 62.75 USD with a low forecast of 50.00 USD and a high forecast of 82.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
10 Buy
4 Hold
1 Sell
Moderate Buy
Current: 38.730
Low
50.00
Averages
62.75
High
82.00
Current: 38.730
Low
50.00
Averages
62.75
High
82.00
About DOCS
Doximity, Inc. provides a digital platform for the United States medical professionals. It offers marketing, hiring, and workflow solutions to pharmaceutical manufacturers, health systems, medical recruiting firms, and other healthcare companies. Its marketing solutions enable its pharmaceutical and health system customers to get the right content, services, and peer connections to the right medical professionals through a variety of modules. Its hiring solutions provide digital recruiting capabilities to health systems and medical recruiting firms, enabling them to identify, connect with, and hire from its network of both active and passive medical professional candidates, who might otherwise be missed through traditional recruiting channels. Its workflow solutions include its telehealth, on-call scheduling, and AI-powered workflow tools, are designed to help clinicians streamline their clinical workflow, reduce their administrative burden, and connect with patients and colleagues.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
